8 ways to get relief from tirzepatide nausea Nearly 15% of people taking tirzepatide or semaglutide , another GLP-1 medication, for obesity discontinue the treatment due to side effects like nausea
Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate
No subscriptions or monthly fees ever
However, evidence from research studies suggests that GLP-1 analogs may also reduce gastric acid secretion, which can impair the conversion of dietary B12 into its absorbable form and decrease binding to intrinsic factor, both of which are necessary for proper absorption
Semaglutide is a GLP-1 receptor agonist with no direct action on renal potassium handling or cellular potassium distribution
PlexusDx evaluates your genetic predisposition to sustained weight loss to personalize a discontinuation timeline that works for your metabolism
.webp)
